NCT05301556已完成不适用
Effect of a Food for Special Medical Purpose (FSMP) Product During the Perioperative Period in Patients With Digestive Tract Tumor
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 326
- 试验地点
- 14
- 主要终点
- Serum Pre-Albumin
研究概览
简要总结
This is a prospective, randomized, controlled, unblinded, parallel, multicenter, and non-inferiority study to demonstrate the safety and efficacy of a Food for Special Medical Purpose product (FSMP) in participants with digestive tract tumor undergoing surgical resection during the perioperative period.
详细描述
This is a prospective, randomized, controlled, unblinded, parallel, and multicenter, and non-inferiority study to demonstrate the safety and efficacy of a FSMP in participants with digestive tract tumor undergoing surgical resection during the perioperative period. Half of the participants will receive FSMP, the other half will receive Enteral Nutrition Emulsion (TPF-T) as an active control.
Prealbumin, albumin, C-reactive protein (CRP), immunology parameters, vital signs, nutrition and safety-related laboratory parameters, compliance, and Adverse Events (AEs) will be evaluated in this study, to demonstrate its parity with TPF-T on efficacy and safety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant is male or female, between 18 and 75 years old, female participant is non-pregnant or non- lactating, at least 6 weeks postpartum
- •Participants with digestive tract tumors diagnosed by histological method or radiological diagnosis and scheduled to undergo surgical resection
- •Participant with NRS-2002 score ≥3
- •Participant is willing to comply with the study protocol, able and willing to consume study product according to the protocol
- •Participants with Body Mass Index 18.5 - 30 kg/m2
- •Participant has voluntarily signed and dated an informed consent form (ICF), approved by an Institutional Review Board (IRB) / Independent Ethics Committee (IEC) prior to any participation in the study
排除标准
- •Participant has an expected life expectancy < 3 months
- •Participant has contraindications to enteral nutrition (such as active gastrointestinal hemorrhage, bowel obstruction, decompensated short bowel syndrome, high flow intestinal fistula, severe intraperitoneal infection, severe gastrointestinal emptying disorder, unstable vital signs, dyscoagulation, severe nausea, vomiting and/or uncontrolled diarrhea/steatorrhoea) that in the opinion of the study physician cannot be corrected
- •Participant used parenteral nutrition or had plasma infused, RBC infused, albumin infused, amino acid infused or undergone radiotherapy and/or chemotherapy within 1 week before screening
- •Participant with serum Albumin <2.5g/dl at the time of the screening
- •Participant has moderate to severe anemia, i.e. Hgb < 90g / L
- •Patients who plan to receive endoscopic tumor resection or / and palliative surgery
- •Participant has renal dysfunction (serum creatinine > 2 times the upper limit of normal (ULN))
- •Participant has liver insufficiency [serum alanine transaminase (ALT) and/or aspartate transaminase (AST) > 2 times the ULN or severe cholestasis (conjugated bilirubin > 2 times the ULN)]
- •Participant has severe cardiac insufficiency (e.g., Severe arrhythmia or atrial fibrillation; myocardial ischemia or stent surgery with unstable cardiac function within 3 months prior to screening visit )
- •Participant states that he/she has had a significant cardiovascular and cerebrovascular event (e.g., myocardial infarction, stroke) within six months prior to screening visit; or stated history of congestive heart failure
- •Participant with type I diabetes, or type II diabetes with fasting blood glucose ≥8mmol/L
- •Participant has history of significant neurological or psychiatric disorder
- •Participant has history of alcoholism, drug abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures
- •Participant has a known history of allergy or intolerance to any ingredient in the investigational products
- •Participant is currently undergoing tumor immunotherapy taking medications/substances that could profoundly modulate appetite, metabolism or inflammatory level
- •Appetite enhancers, pregnancy promoters, steroids (nasal inhalation, topical and optical steroids are acceptable);
- •Anti-inflammatory fat emulsions or other oral nutritional supplementations/drugs containing Omega-3 fatty acids, protein, glutamine, or arginine.
- •Dexamethasone, growth hormone or other drugs affecting metabolism;
- •Participant is currently undergoing tumor immunotherapy or taking medications/substances that could profoundly modulate immune function, such as PD1 or PDL1 inhibitors; CTLA-4 inhibitor; Thymosin; Azathioprine; Cyclosporine; Tacrolimus; Tumor necrosis factor antagonist; Lentinan; immune-modulating Chinese medicine
- •Participant with active tuberculosis and HIV infection
- •Participant participated in any clinical trial within four weeks prior to the screening visit.
结局指标
主要结局
Serum Pre-Albumin
时间窗: Baseline to Post Op Day (POD) 9
Change in pre-albumin
次要结局
- Serum Albumin(Baseline to Post Op Day (POD) 9)
- Weight(Baseline to Post Op Day (POD) 9)
- Nutritional Risk Screening (NRS) 2002(Baseline to Post Op Day (POD) 9)
研究者
研究点 (14)
Loading locations...
相似试验
招募中
不适用
Effect of an Amino Acids and Flavonoids Containing FSMP on Chemotherapy Toxicity, Nutritional Status and Quality of Life in Breast Cancer PatientsBreast CancerNCT05968677Flavolife Srl60
进行中（未招募）
不适用
Efficacy and Tolerability of a Specialized Food Products for Dietary Therapeutic and Preventive Nutrition Based on Ice Cream (Ice Cream With Brazzein, Maltitol and Oligofructose; Ice Cream With Brazzein, Erythritol, Maltitol and Inulin) Compared to Standard (Sundae) Ice CreamNon-Alcoholic Steatohepatitis (NASH)Diabetes Mellitus Type 2 (T2DM)NCT06724913Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology100
已完成
不适用
The Influence of Food for Special Dietary Use - Spread Enriched With 5-hydroxytryptophan, Theanine and Gamma-aminobutyric Acid on Psychophysiological Functions of Subjects Without Meaningful Organic and Cognitive PathologyCognitive ChangeEmotional RegulationConcentration Ability ImpairedDisturbance, Mild MemoryNCT05543811Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology140
已完成
1 期
Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With RitonavirHCV InfectionNCT00909311Abbott8
撤回
2 期
A Placebo-Controlled, Randomized, Safety and Efficacy Study to Evaluate the Change in Hemoglobin A1c Levels in Type 2 Diabetic Subjects While Taking NutralinDiabetesNCT01275027Avera McKennan Hospital & University Health Center